45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
80,825
Insurances with rates
28
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 50010218 | Imjudo (tremelimumab-ACTL) 20 mg/mL Inj 15mL | $288,840 | $144,420 | — | — | 6 |
| 50010218 | Imjudo (tremelimumab-ACTL) 20 mg/mL Inj 15mL | $288,840 | $144,420 | — | — | 11 |
| 50010218 | Imjudo (tremelimumab-ACTL) 20 mg/mL Inj 15mL | $288,840 | $144,420 | — | — | 9 |
| 50300287 | Sipuleucel-T >/ 50 million cells / 250mL LR | $253,329 | $126,665 | — | — | 6 |
| 50300287 | Sipuleucel-T >/ 50 million cells / 250mL LR | $253,329 | $126,665 | — | — | 11 |
| 50300287 | Sipuleucel-T >/ 50 million cells / 250mL LR | $253,329 | $126,665 | — | — | 9 |
| 50010242 | Pegloticase (Krystexxa) 8mg/mL Inj | $222,406 | $111,203 | — | — | 6 |
| 50010242 | Pegloticase (Krystexxa) 8mg/mL Inj | $222,406 | $111,203 | — | — | 11 |
| 50010242 | Pegloticase (Krystexxa) 8mg/mL Inj | $222,406 | $111,203 | — | — | 9 |
| 50010098 | Alemtuzumab 10mg/mL Inj 1.2mL dns | $218,168 | $109,084 | — | — | 6 |
| 50010098 | Alemtuzumab 10mg/mL Inj 1.2mL dns | $218,168 | $109,084 | — | — | 11 |
| 50010098 | Alemtuzumab 10mg/mL Inj 1.2mL dns | $218,168 | $109,084 | — | — | 9 |
| 50010207 | Ocrelizumab 300 mg/10 mL Inj | $146,126 | $73,063 | — | — | 6 |
| 50010207 | Ocrelizumab 300 mg/10 mL Inj | $146,126 | $73,063 | — | — | 11 |
| 50010207 | Ocrelizumab 300 mg/10 mL Inj | $146,126 | $73,063 | — | — | 9 |
| 50010215 | Teprotumumab-TRBW (Tepezza) 500 mg Inj | $129,822 | $64,911 | — | — | 6 |
| 50010215 | Teprotumumab-TRBW (Tepezza) 500 mg Inj | $129,822 | $64,911 | — | — | 11 |
| 50010215 | Teprotumumab-TRBW (Tepezza) 500 mg Inj | $129,822 | $64,911 | — | — | 9 |
| 50010115 | Ipilimumab 5mg/mL inj 40mL | $116,041 | $58,021 | — | — | 6 |
| 50010115 | Ipilimumab 5mg/mL inj 40mL | $116,041 | $58,021 | — | — | 11 |
| 50010115 | Ipilimumab 5mg/mL inj 40mL | $116,041 | $58,021 | — | — | 9 |
| FMC-9816454 | KIT VAL AO SAP3 ULT RSL 20MM | $107,100 | $53,550 | — | — | 6 |
| FMC-9816454 | KIT VAL AO SAP3 ULT RSL 20MM | $107,100 | $53,550 | — | — | 12 |
| FMC-9816455 | KIT VAL AO SAP3 ULT RSL 23MM | $107,100 | $53,550 | — | — | 6 |
| FMC-9816455 | KIT VAL AO SAP3 ULT RSL 23MM | $107,100 | $53,550 | — | — | 12 |
| FMC-9816457 | KIT VAL AO SAP3 ULT RSL 29MM | $107,100 | $53,550 | — | — | 6 |
| FMC-9816457 | KIT VAL AO SAP3 ULT RSL 29MM | $107,100 | $53,550 | — | — | 12 |
| FMC-9816454 | KIT VAL AO SAP3 ULT RSL 20MM | $107,100 | $53,550 | — | — | 8 |
| FMC-9816455 | KIT VAL AO SAP3 ULT RSL 23MM | $107,100 | $53,550 | — | — | 8 |
| FMC-9816457 | KIT VAL AO SAP3 ULT RSL 29MM | $107,100 | $53,550 | — | — | 8 |
| 50300261 | Pertuzumab 1200mg-Trastuz 600mg HY-zzxf/ 15mL inj | $103,222 | $51,611 | — | — | 6 |
| 50300261 | Pertuzumab 1200mg-Trastuz 600mg HY-zzxf/ 15mL inj | $103,222 | $51,611 | — | — | 11 |
| 50300261 | Pertuzumab 1200mg-Trastuz 600mg HY-zzxf/ 15mL inj | $103,222 | $51,611 | — | — | 9 |
| 50010213 | Tildrakizumab-asmn 100 mg/mL inj syringe | $99,415 | $49,708 | — | — | 6 |
| 50010213 | Tildrakizumab-asmn 100 mg/mL inj syringe | $99,415 | $49,708 | — | — | 11 |
| 50010213 | Tildrakizumab-asmn 100 mg/mL inj syringe | $99,415 | $49,708 | — | — | 9 |
| 50300272 | Luspatercept-aamt 75 mg Inj | $96,117 | $48,058 | — | — | 6 |
| 50300272 | Luspatercept-aamt 75 mg Inj | $96,117 | $48,058 | — | — | 11 |
| 50300272 | Luspatercept-aamt 75 mg Inj | $96,117 | $48,058 | — | — | 9 |
| 50300279 | mitoMYcin 4 mg/mL ureteral gel Jelmyto 80mg kit | $80,794 | $40,397 | — | — | 6 |
| 50300279 | mitoMYcin 4 mg/mL ureteral gel Jelmyto 80mg kit | $80,794 | $40,397 | — | — | 11 |
| 50300279 | mitoMYcin 4 mg/mL ureteral gel Jelmyto 80mg kit | $80,794 | $40,397 | — | — | 9 |
| 50010225 | Skyrizi (Risankizumab-RZAA) 600mg inj | $76,998 | $38,499 | — | — | 6 |
| 50010225 | Skyrizi (Risankizumab-RZAA) 600mg inj | $76,998 | $38,499 | — | — | 11 |
| 50010225 | Skyrizi (Risankizumab-RZAA) 600mg inj | $76,998 | $38,499 | — | — | 9 |
| 50251010 | Cabotegravir 600mg/3mL-Rilpivirine 900mg/3mL Inj K | $72,415 | $36,208 | — | — | 6 |
| 50251010 | Cabotegravir 600mg/3mL-Rilpivirine 900mg/3mL Inj K | $72,415 | $36,208 | — | — | 11 |
| 50251010 | Cabotegravir 600mg/3mL-Rilpivirine 900mg/3mL Inj K | $72,415 | $36,208 | — | — | 9 |
| 50010159 | Daratumumab/Hyaluronidase-fihj 1800mg-30000 units/ | $71,610 | $35,805 | — | — | 6 |
| 50010159 | Daratumumab/Hyaluronidase-fihj 1800mg-30000 units/ | $71,610 | $35,805 | — | — | 11 |
Showing top 50 of 80,825 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.